Beijing Gene Testing Technology Company GeneCast Raised Over ￥300 Million in a Series D1 Round Funding Led by a Fund Under CCI Fund

Beijing gene testing technology company GeneCast raised over ￥300 million in a series D1 round funding led by a Fund Under CCI Fund, and followed by Cowin VC, Yahui Precision Medical Fund, and Matrix Partner China. The investment will be used on platform building, introduction of overseas technology, enhanced international cooperation, and brand markeing.

Established in 2014, GeneCast focuses on second generation sequencing technology and bio-informatics. It provides non-invasive precision treatment and companion diagnostics targeting individual tumor.